Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fulcrum Therapeutics (FULC) has announced the granting of inducement stock options to a new employee under its 2022 Inducement Stock Incentive Plan. The company granted 63,000 options to purchase common stock at an exercise price of $3.81 per share, which was the closing price on February 3, 2025.
The options have a ten-year term and follow a four-year vesting schedule: 25% vests on the first employment anniversary, followed by 6.25% vesting quarterly over the next twelve quarters. The vesting is contingent upon continued employment with Fulcrum through the applicable dates. This grant was made in accordance with Nasdaq Listing Rule 5635(c)(4).
Fulcrum Therapeutics (FULC) ha annunciato l'assegnazione di opzioni azionarie di incentivazione a un nuovo dipendente nell'ambito del suo Piano di Incentivazione Azionaria 2022. La società ha concesso 63.000 opzioni per l'acquisto di azioni ordinarie a un prezzo di esercizio di 3,81 $ per azione, che era il prezzo di chiusura del 3 febbraio 2025.
Le opzioni hanno un termine di dieci anni e seguono un programma di maturazione di quattro anni: il 25% matura al primo anniversario di assunzione, seguito da un 6,25% che matura trimestralmente nei successivi dodici trimestri. La maturazione è subordinata al mantenimento dell'impiego con Fulcrum fino alle date applicabili. Questa concessione è stata effettuata in conformità con la Regola di Listing Nasdaq 5635(c)(4).
Fulcrum Therapeutics (FULC) ha anunciado la concesión de opciones sobre acciones como incentivo a un nuevo empleado bajo su Plan de Incentivación de Acciones 2022. La compañía otorgó 63,000 opciones para comprar acciones ordinarias a un precio de ejercicio de $3.81 por acción, que era el precio de cierre del 3 de febrero de 2025.
Las opciones tienen un plazo de diez años y siguen un calendario de adquisición de cuatro años: el 25% se adquiere en el primer aniversario de empleo, seguido de un 6,25% que se adquiere trimestralmente durante los siguientes doce trimestres. La adquisición está sujeta a la continuidad del empleo en Fulcrum durante las fechas aplicables. Esta concesión se realizó de acuerdo con la Regla de Cotización 5635(c)(4) de Nasdaq.
풀크럼 테라퓨틱스(FULC)는 2022 유인 주식 인센티브 계획에 따라 새로운 직원에게 유인 주식 옵션을 부여했다고 발표했습니다. 회사는 63,000개의 옵션을 주당 $3.81의 행사 가격으로 보통주를 구매할 수 있도록 부여했습니다. 이는 2025년 2월 3일의 거래 마감 가격이었습니다.
이 옵션은 10년의 기간을 가지며 4년의 취득 일정에 따릅니다: 첫 고용 기념일에 25%가 취득되고, 이후 12개 분기 동안 분기마다 6.25%가 취득됩니다. 취득은 해당 날짜까지 풀크럼에서의 지속적인 고용에 따라 달라집니다. 이 부여는 나스닥 상장 규칙 5635(c)(4)에 따라 이루어졌습니다.
Fulcrum Therapeutics (FULC) a annoncé l'attribution d'options d'achat d'actions à un nouvel employé dans le cadre de son Plan d'Incentives d'Achat d'Actions 2022. L'entreprise a octroyé 63 000 options pour l'achat d'actions ordinaires à un prix d'exercice de 3,81 $ par action, qui correspondait au prix de clôture du 3 février 2025.
Les options ont une durée de dix ans et suivent un calendrier d'acquisition de quatre ans : 25 % sont acquises au premier anniversaire d'emploi, suivies de 6,25 % qui s'acquièrent trimestriellement au cours des douze trimestres suivants. L'acquisition dépend de la continuité de l'emploi chez Fulcrum jusqu'aux dates prévues. Cette attribution a été faite conformément à la règle d'inscription Nasdaq 5635(c)(4).
Fulcrum Therapeutics (FULC) hat die Gewährung von Anreiz-Aktienoptionen an einen neuen Mitarbeiter im Rahmen seines Anreiz-Aktienplans 2022 angekündigt. Das Unternehmen vergab 63.000 Optionen, um Stammaktien zu einem Ausübungspreis von 3,81 $ pro Aktie zu erwerben, der den Schlusskurs am 3. Februar 2025 darstellt.
Die Optionen haben eine Laufzeit von zehn Jahren und folgen einem vierjährigen Vesting-Zeitplan: 25% vesten am ersten Jahrestag der Beschäftigung, gefolgt von 6,25%, die vierteljährlich über die nächsten zwölf Quartale vesten. Das Vesting ist abhängig von der fortgesetzten Beschäftigung bei Fulcrum bis zu den geltenden Daten. Diese Gewährung erfolgte gemäß Nasdaq-Listing-Regel 5635(c)(4).
- None.
- None.
CAMBRIDGE, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to a new employee. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employee entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).
Fulcrum granted the new employee 63,000 options to purchase shares of the company’s common stock at an exercise price of
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead program in clinical development is pociredir, a small molecule designed to increase expression of fetal hemoglobin and in development for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.
Contact:
Chris Calabrese
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com
917-680-5608
FAQ
What is the exercise price of FULC's new stock options granted on February 3, 2025?
How many stock options did FULC grant to the new employee in February 2025?
What is the vesting schedule for FULC's February 2025 inducement stock options?
How long is the term of FULC's February 2025 inducement stock options?
